InspirMed to Present at the 23rd International Society for Aerosols in Medicine (ISAM) Congress
26 Abril 2021 - 4:30AM
InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that
specializes in the development of inhalable liposome formulation
programs, announced today that a late-breaking abstract describing
the potential advantages of ISPM21 and ISPM19 has been accepted by
the scientific committee for poster presentation at the 23rd
International Society for Aerosols in Medicine (ISAM) Congress.
The poster, titled “A Strategy to Treat COVID-19
with Targeted Delivery of Inhalable Liposomal Antiviral Drugs”, has
a poster number of 072 (New Devices and Emerging Therapies) and
will be posted both on the website (www.isam.org) with an
opportunity for a short oral presentation and printed for display
at the Boise Conference Center for live presentation in Boise,
Idaho, USA, on May 22-26, 2021.
ISAM Congress will gather hundreds of attendees
including clinicians, respiratory health care professionals,
critical care professionals, aerosol scientists and engineers,
formulations scientists, and product development and regulatory
experts at one of the world’s largest pulmonary drug delivery and
respiratory health conferences. The objective of the Congress is to
foster scientific discussions around the current state-of-the-art
for aerosols in medicine.
TLC previously presented an inhalable liposomal
nintedanib for enhanced treatment of pulmonary diseases at the 22nd
ISAM Congress in Switzerland. The link to the abstract (N-003) for
the poster presentation can be found on page A-13 under the New
Devices and Emerging Therapies section of the Journal of Aerosol
Medicine and Pulmonary Drug Delivery
(https://www.liebertpub.com/doi/pdf/10.1089/jamp.2019.ab02.abstracts).
About ISPM21
ISPM21 is a proprietary inhalable liposome
formulation of GS-441524, the active ingredient that reaches the
lungs following administration of remdesivir. Originally indicated
for the treatment of hepatitis, remdesivir has shown efficacy in
inhibiting viral replication of the SARS-CoV-2 virus that causes
COVID-19 and is approved by the US Food & Drug Administration
(FDA) for the treatment of COVID-19 requiring hospitalization.
GS-441524’s favorable chemical properties – low molecular weight,
greater hydrophilicity, greater localization to AT1/2 cells and
ability to cross the blood-brain-barrier – make it a promising
candidate as a therapeutic or prophylactic agent for COVID-19.
However, the low oral bioavailability of GS-441524 means an
extremely high oral dose would be required to achieve therapeutic
levels. By encapsulating GS-441524 in an inhalable liposome
formulation (ISPM21), there is no need for the complex excipient
cyclodextrin, thus potentially eliminating nephrotoxicity, and
targeted delivery by inhalation of liposomes enables increased
availability and prolonged exposure of the active drug in the
lungs.
About ISPM19
ISPM19, formerly known as TLC19, is a
proprietary inhalable liposome formulation of hydroxychloroquine
(HCQ). HCQ has shown potential in prophylaxis and/or treatment for
COVID-19 in in vitro and preliminary clinical trial studies, but
orally administered HCQ cannot reach therapeutic levels due to its
dose-limiting toxicities. ISPM19 utilizes ~1% of the highest oral
HCQ dose tested and delivers the drug directly to the airways and
lungs, potentially avoiding systemic toxicities associated with
oral HCQ while providing a sustained effective concentration at the
primary site of infection. ISPM19 is designed to be cost-effective,
easily accessible and can be self-administered with a portable
nebulizer. A Phase 1 randomized, vehicle-controlled, blinded study
to assess the safety, tolerability, and pharmacokinetics of
ascending doses of inhaled ISPM19 in healthy volunteer subjects is
ongoing.
About InspirMed
InspirMed is a newly established subsidiary of
TLC specializing in the development of inhalable liposome
formulation programs for severe acute and chronic pulmonary
diseases. TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage,
specialty pharmaceutical company dedicated to the research and
development of novel nanomedicines that maximize the potential of
its proprietary lipid-assembled drug delivery platform (LipAD™),
including BioSeizer® sustained release technology and NanoX™ active
drug loading technology, which are versatile in the choice of
active pharmaceutical ingredients and scalable in
manufacturing.
Contact
Dawn Chi
Corporate Communications
dawn@tlcbio.com
Taiwan Liposome (NASDAQ:TLC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Taiwan Liposome (NASDAQ:TLC)
Gráfica de Acción Histórica
De May 2023 a May 2024